Evidence map›Paper›PMID 26147651›Full record

Trial reportPloS one2015

NK Cells of Kidney Transplant Recipients Display an Activated Phenotype that Is Influenced by Immunosuppression and Pathological Staging.

Ulrike Hoffmann, Christine Neudörfl, Kerstin Daemen, Jana Keil, Maja Stevanovic-Meyer, Frank Lehner, Hermann Haller, Cornelia Blume, Christine S Falk

Registry-linked trialOpen access · goldAbstract readComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07718308 (A Multicenter Exploratory Clinical Study of Targeted NK Cell Inhibition for Transplant Kidney Chronic Active Antibody-Mediated Rejection), which is not on this map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07718308 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Multicenter Exploratory Clinical Study of Targeted NK Cell Inhibition for Transplant Kidney Chronic Active Antibody-Mediated Rejection (caABMR): Single Induction With CD38 Monoclonal Antibody Followed by Sequential Maintenance With Azathioprine

TypeinterventionalSponsorwujianyongRan2026 to 2028Enrolled20ConditionsKidney Transplantation, Antibody-mediated RejectionArmsCD38, Azathioprine (AZA), Standard Triple Immunosuppression Maintenance
3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Review
  3. Immune Landscape in Kidney Transplantation.Journal of inflammation research · 2025
    Review
  4. Review
  5. Article
  6. Article
  7. Cellular Senescence and Frailty in Transplantation.Current transplantation reports · 2023
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Cellular Senescence in the Kidney.Journal of the American Society of Nephrology : JASN · 2019
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Ulrike HoffmannInstitute of Transplant Immunology, IFB-Tx, Hannover Medical School Hannover, Hannover, Germany.
Christine NeudörflInstitute of Transplant Immunology, IFB-Tx, Hannover Medical School Hannover, Hannover, Germany.
Kerstin DaemenInstitute of Transplant Immunology, IFB-Tx, Hannover Medical School Hannover, Hannover, Germany.
Jana KeilInstitute of Transplant Immunology, IFB-Tx, Hannover Medical School Hannover, Hannover, Germany.
Maja Stevanovic-MeyerInstitute of Transplant Immunology, IFB-Tx, Hannover Medical School Hannover, Hannover, Germany.
Frank LehnerDepartment of Visceral and Transplant Surgery, Hannover Medical School, Hannover, Germany.
Hermann HallerDepartment of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany.
Cornelia BlumeDepartment of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany; Institute of Technical Chemistry, Leibniz University Hannover, Hannover, Germany.
Christine S FalkInstitute of Transplant Immunology, IFB-Tx, Hannover Medical School Hannover, Hannover, Germany; DZIF, German Center for Infectious Diseases, Hannover / Braunschweig, Germany.
Medizinische Hochschule Hannover · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To explore phenotype and function of NK cells in kidney transplant recipients, we investigated the peripheral NK cell repertoire, capacity to respond to various stimuli and impact of immunosuppressive drugs on NK cell activity in kidney transplant recipients. CD56dim NK cells of kidney transplanted patients displayed an activated phenotype characterized by significantly decreased surface expression of CD16 (p=0.0003), CD226 (p<0.0001), CD161 (p=0.0139) and simultaneously increased expression of activation markers like HLA-DR (p=0.0011) and CD25 (p=0.0015). Upon in vitro stimulation via Ca++-dependent signals, down-modulation of CD16 was associated with induction of interferon (IFN)-γ expression. CD16 modulation and secretion of NFAT-dependent cytokines such as IFN-γ, TNF-α, IL-10 and IL-31 were significantly suppressed by treatment of isolated NK cells with calcineurin inhibitors but not with mTOR inhibitors. In kidney transplant recipients, IFN-γ production was retained in response to HLA class I-negative target cells and to non-specific stimuli, respectively. However, secretion of other cytokines like IL-13, IL-17, IL-22 and IL-31 was significantly reduced compared to healthy donors. In contrast to suppression of cytokine expression at the transcriptional level, cytotoxin release, i.e. perforin, granzyme A/B, was not affected by immunosuppression in vitro and in vivo in patients as well as in healthy donors. Thus, immunosuppressive treatment affects NK cell function at the level of NFAT-dependent gene expression whereby calcineurin inhibitors primarily impair cytokine secretion while mTOR inhibitors have only marginal effects. Taken together, NK cells may serve as indicators for immunosuppression and may facilitate a personalized adjustment of immunosuppressive medication in kidney transplant recipients.

Indexed as

Immunosuppression TherapyKidney TransplantationAdultAgedAntigens, CDCalcium SignalingCytokinesFemaleHumansImmunosuppressive AgentsKiller Cells, NaturalMaleMiddle AgedTransplantation ToleranceAntigens, CDCytokinesImmunosuppressive Agents

Identifiers

PMID26147651
PMCPMC4492590
OpenAlexW835157305

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.